Drug Channels

SEPTEMBER 21, 2022

The battle for control of the specialty patient continues. In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs. d/b/a Drug Channels Institute. Read on for full details and the latest data.

Specialty Pharmacies 97

Specialty Pharmacies Hospitals Pharmacy Pharmaceuticals 97

Drug Channels

DECEMBER 13, 2023

This week, I’m rerunning some popular posts while I prepare for Fiday's Drug Channels Outlook 2024 live video webinar. Time for our annual update on the channels for provider-administered drugs. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Pharmaceuticals Production 98

Drug Channels

SEPTEMBER 13, 2023

Time for our annual update on the channels for provider-administered drugs. For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. d/b/a Drug Channels Institute.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Pharmaceuticals Production 97

Drug Channels

APRIL 8, 2022

Michael discusses patient support challenges that are unique to specialty-lite pharmaceuticals. He goes on to describe four new categories of patient solutions and pharmacy models specific to this growing market segment. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Specialty Pharmacies 96

Specialty Pharmacies Pharmacy Production Pharmaceuticals 96

Drug Discovery World

FEBRUARY 22, 2023

Craig Caceci, Managing Director at Terebellum, offers guidance to pharmaceutical companies that are in the position to take their drugs to market. The challenges are even greater in the case of orphan drugs where patients need to be identified; therefore, emphasis is on diagnosis. There are many questions to ask.

Specialty Pharmacies 130

Specialty Pharmacies Drugs Marketing Clinical Trials 130

Drug Channels

OCTOBER 10, 2023

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: U.S.

Pharmaceuticals 40

Pharmaceuticals Specialty Pharmacies Pharmacy Biosimilars 40

Drug Channels

SEPTEMBER 21, 2020

This important event convenes key stakeholders including manufacturers, specialty pharmacies, hubs, payers, PBMs, physicians and more to explore strategies for developing and integrating hub programs and other patient-centric services to ensure product access and optimal reimbursement. Drug Channels, or any of its employees.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Production 52

Drug Channels

JULY 20, 2021

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Marketing Pharmaceuticals 52

Drug Channels

NOVEMBER 8, 2020

Drug Channels readers will save $200 off the standard rate when they use code KTP933 and register prior to November 20th.*. Drug Channels readers will save $200 off the standard rate when they use code KTP933 and register prior to November 20th.*. Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Pharmaceuticals 52

Drug Channels

MARCH 15, 2022

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S.

Pharmacy 98

Pharmacy Specialty Pharmacies Licensing Licensing 98

Drug Channels

OCTOBER 19, 2020

Drug Channels readers will save $300 off the standard rate when they use code GJE973 and register prior to October 30th.*. Drug Channels readers will save $300 off the standard rate when they use code GJE973 and register prior to October 30th.*. Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

Drug Channels

JANUARY 4, 2021

Drug Channels readers will save $100 off the current registration rate when they use code HUBSDC10*. Drug Channels readers will save $100 off the current registration rate when they use code HUBSDC10*. Drug Channels, or any of its employees. d/b/a Drug Channels Institute. REGISTER TODAY !

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Production 52

Drug Channels

APRIL 19, 2021

Drug Channels, or any of its employees. To find out how you can reach the Drug Channels audience, please contact Paula Fein (paula@DrugChannels.net). d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Copyright © 2006-2021 Pembroke Consulting, Inc.

Compliance 40

Compliance Production Specialty Pharmacies Pharmacy 40

Drug Channels

APRIL 11, 2021

Drug Channels readers save 10% off the current registration rate with promo code 21PSSDC10.* Drug Channels, or any of its employees. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Register today. Koob, Assistant U.S. Attorney , U.S. Register today.

Specialty Pharmacies 40

Specialty Pharmacies Compliance Pharmacy Pharmaceuticals 40

The Pharma Data

JANUARY 12, 2021

Akin to the NASA Deep Space Network, SYNERGY-AI OCTCC is a real time data and communication network between patients, sites, and pharmaceutical companies, with the Massive Bio AI-enabled engine orchestrating these stakeholders for successful operations. NEW YORK–( BUSINESS WIRE )– Massive Bio, Inc. , 75N91020C00016.

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceutical Companies 52

The Pharma Data

OCTOBER 27, 2020

Food and Drug Administration (FDA) in support of an efficacy supplement to the Tyvaso new drug application (sNDA), which we expect to result in revised labeling reflecting the outcome of the INCREASE study. We submitted a 505(b)(1) new drug application (NDA) to the FDA for our Trevyent disposable treprostinil pump system in June 2019.

FDA 40

FDA Production Licensing Licensing 40